Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from X4 Pharmaceuticals ( (XFOR) ).
On August 22, 2025, X4 Pharmaceuticals, Inc. announced the resignation of David McGirr and R. Keith Woods from its board of directors, including all committees. Their resignations were not due to any disagreements with the company regarding its operations, policies, or practices. Following these resignations, Michael Wyzga was appointed as chair of the audit committee, while Francoise de Craecker and Gary Bridger were appointed as members of the committee.
The most recent analyst rating on (XFOR) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on X4 Pharmaceuticals stock, see the XFOR Stock Forecast page.
Spark’s Take on XFOR Stock
According to Spark, TipRanks’ AI Analyst, XFOR is a Neutral.
X4 Pharmaceuticals faces significant financial challenges, notably in profitability and cash flow, despite growth in revenue. Technical indicators suggest a downward trend, while valuation metrics indicate potential undervaluation. The earnings call and recent corporate events offer some optimism with strategic initiatives and clinical progress, but market and sales challenges remain.
To see Spark’s full report on XFOR stock, click here.
More about X4 Pharmaceuticals
Average Trading Volume: 4,092,424
Technical Sentiment Signal: Sell
Current Market Cap: $88M
For detailed information about XFOR stock, go to TipRanks’ Stock Analysis page.